These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 19694226)

  • 21. Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study.
    Curro' D; Vuolo L; Gualandi F; Bacigalupo A; Roccatagliata L; Capello E; Uccelli A; Saccardi R; Sormani MP; Mancardi G
    Mult Scler; 2015 Oct; 21(11):1423-30. PubMed ID: 25583838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Future for Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes.
    van Megen KM; van 't Wout ET; Forman SJ; Roep BO
    Front Immunol; 2018; 9():690. PubMed ID: 29696017
    [No Abstract]   [Full Text] [Related]  

  • 23. Combined Immunosuppressive Therapy Induces Remission in Patients With Severe Type B Insulin Resistance: A Prospective Cohort Study.
    Klubo-Gwiezdzinska J; Lange M; Cochran E; Semple RK; Gewert C; Brown RJ; Gorden P
    Diabetes Care; 2018 Nov; 41(11):2353-2360. PubMed ID: 30201849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complete remission of Crohn's disease after high-dose cyclophosphamide and autologous stem cell transplantation.
    Kreisel W; Potthoff K; Bertz H; Schmitt-Graeff A; Ruf G; Rasenack J; Finke J
    Bone Marrow Transplant; 2003 Aug; 32(3):337-40. PubMed ID: 12858208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hematopoietic stem cell transplantation for the treatment of autoimmunity in type 1 diabetes.
    LoCascio SA; Spinelli J; Kurtz J
    Curr Stem Cell Res Ther; 2011 Mar; 6(1):29-37. PubMed ID: 20955158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus.
    Burt RK; Traynor A; Statkute L; Barr WG; Rosa R; Schroeder J; Verda L; Krosnjar N; Quigley K; Yaung K; Villa Bs M; Takahashi M; Jovanovic B; Oyama Y
    JAMA; 2006 Feb; 295(5):527-35. PubMed ID: 16449618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New Horizons in the Treatment of Type 1 Diabetes: More Intense Immunosuppression and Beta Cell Replacement.
    Couri CEB; Malmegrim KCR; Oliveira MC
    Front Immunol; 2018; 9():1086. PubMed ID: 29868031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma.
    Shimoni A; Smith TL; Aleman A; Weber D; Dimopoulos M; Anderlini P; Andersson B; Claxton D; Ueno NT; Khouri I; Donato M; Korbling M; Alexanian R; Champlin R; Giralt S
    Bone Marrow Transplant; 2001 Apr; 27(8):821-8. PubMed ID: 11477439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-infusion of autologous adipose tissue derived insulin-secreting mesenchymal stem cells and bone marrow derived hematopoietic stem cells: viable therapy for type III.C. a diabetes mellitus.
    Thakkar UG; Vanikar AV; Trivedi HL
    Biomed J; 2013; 36(6):304-7. PubMed ID: 24385073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intensive immunoablation and autologous blood stem cell transplantation in patients with refractory rheumatoid arthritis: the University of Nebraska experience.
    Pavletic SZ; Odell JR; Pirruccello SJ; Ursick MM; Haire CE; Sharp JG; Kessinger A; Klassen LW
    J Rheumatol Suppl; 2001 Oct; 64():13-20. PubMed ID: 11642497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stem cell therapies for type 1 diabetes mellitus.
    Voltarelli JC; Couri CE; Rodrigues MC; Moraes DA; Stracieri AB; Pieroni F; Navarro G; Leal AM; Simões BP
    Indian J Exp Biol; 2011 Jun; 49(6):395-400. PubMed ID: 21702217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study.
    Kang HJ; Shin HY; Park JE; Chung NG; Cho B; Kim HK; Kim SY; Lee YH; Lim YT; Yoo KH; Sung KW; Koo HH; Im HJ; Seo JJ; Park SK; Ahn HS;
    Biol Blood Marrow Transplant; 2010 Nov; 16(11):1582-8. PubMed ID: 20685256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial.
    Burt RK; Shah SJ; Dill K; Grant T; Gheorghiade M; Schroeder J; Craig R; Hirano I; Marshall K; Ruderman E; Jovanovic B; Milanetti F; Jain S; Boyce K; Morgan A; Carr J; Barr W
    Lancet; 2011 Aug; 378(9790):498-506. PubMed ID: 21777972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intense immunosuppressive therapy followed by autologous peripheral blood selected progenitor cell reinfusion for severe autoimmune disease.
    Musso M; Porretto F; Crescimanno A; Bondi F; Polizzi V; Scalone R
    Am J Hematol; 2001 Feb; 66(2):75-9. PubMed ID: 11421302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.
    Ballester OF; Agaliotis DP; Hiemenz JW; Janssen WE; Fields KK; Zorksy PE; Goldstein SC; Perkins JB; Elfenbein GJ
    Bone Marrow Transplant; 1996 Jul; 18(1):9-14. PubMed ID: 8831989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
    Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Control of severe systemic lupus erythematosus after high-dose immunusuppressive therapy and transplantation of CD34+ purified autologous stem cells from peripheral blood.
    Fouillard L; Gorin NC; Laporte JP; Leon A; Brantus JF; Miossec P
    Lupus; 1999; 8(4):320-3. PubMed ID: 10413212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A modified myeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation, consisting of intravenous busulfan, cyclophosphamide and total lymphoid irradiation, in advanced leukemia].
    Nakamae H; Terada Y; Nakane T; Koh H; Nakamae M; Aimoto R; Hirose A; Hayashi Y; Nishimoto M; Inoue E; Yoshimura T; Inoue A; Koh KR; Yamane T; Hino M
    Gan To Kagaku Ryoho; 2010 Sep; 37(9):1691-5. PubMed ID: 20841930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-total body irradiation myeloablative conditioning with intravenous busulfan and cyclophosphamide in hematopoietic stem cell transplantation for malignant infantile osteopetrosis.
    Behfar M; Dehghani SS; Hosseini AS; Jalali A; Hamidieh AA; Ghavamzadeh A
    Pediatr Transplant; 2015 Jun; 19(4):422-7. PubMed ID: 25879376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.